Clinical Trial Update: Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Pentostatin, Cyclophosphamide, and Rituximab for poor-prognosis chronic graft-versus-host disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Pentostatin (pentostatin)
• Rituximab (rituximab)

Snippet

Sponsor: University of Rochester | Conditions: Active Chronic Graft Versus Host Disease | Phase 2 | Status: WITHDRAWN